J B Chemicals & Pharmaceuticals Ltd's Q3FY25 Quarter Results
- 05 Feb 2025
Result Summary
- J B Chemicals & Pharmaceuticals Ltd reported a 3.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 14.0%.
- Its expenses for the quarter were down by 2.7% QoQ and up 12.8% YoY.
- The net profit decreased 6.9% QoQ and increased 21.7% YoY.
- The earnings per share (EPS) of J B Chemicals & Pharmaceuticals Ltd stood at 10.2 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 971.49 | 1010.57 | 851.86 | -3.9% | 14.0% |
Total Expenses | 753.50 | 774.04 | 667.91 | -2.7% | 12.8% |
Profit Before Tax | 217.99 | 236.53 | 183.95 | -7.8% | 18.5% |
Tax | 55.50 | 61.96 | 50.38 | -10.4% | 10.2% |
Profit After Tax | 162.49 | 174.57 | 133.57 | -6.9% | 21.7% |
Earnings Per Share | 10.20 | 11.00 | 8.50 | -7.3% | 20.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
J B Chemicals & Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, known for producing a diverse range of products. The company specializes in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Over the years, it has established a strong presence in both domestic and international markets. The company's product portfolio includes various therapeutic segments such as gastrointestinal, cardiovascular, anti-infectives, and anti-allergics. J B Chemicals has been focusing on expanding its market reach by enhancing its product offerings and scaling its operations. Currently, there are no specific recent developments provided, but the company is known for its strategic initiatives to bolster growth and innovation in the pharmaceutical sector.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), J B Chemicals & Pharmaceuticals Ltd reported a total income of ₹971.49 crores. This marks a 14.0% increase from the same quarter in the previous year (Q3FY24), which recorded a total income of ₹851.86 crores. However, there is a decline of 3.9% when compared to the second quarter of fiscal year 2025 (Q2FY25), where the total income was noted at ₹1010.57 crores. This quarterly fluctuation may reflect the dynamic nature of the pharmaceutical market, affected by factors such as product demand and market conditions. The year-over-year growth indicates a positive trajectory in revenue generation for the company.
Profitability
The company's profitability metrics for Q3FY25 show a mixed performance. The profit before tax (PBT) for the quarter was ₹217.99 crores, showing an 18.5% increase from Q3FY24, which had a PBT of ₹183.95 crores. However, this represents a decline of 7.8% from Q2FY25, where the PBT was ₹236.53 crores. Correspondingly, the profit after tax (PAT) for Q3FY25 was ₹162.49 crores, which is a 21.7% rise compared to Q3FY24’s ₹133.57 crores but a 6.9% decrease from Q2FY25’s ₹174.57 crores. The tax expenses for Q3FY25 stood at ₹55.50 crores, which is a decline from both the previous quarter (₹61.96 crores) and the same quarter last year (₹50.38 crores). The earnings per share (EPS) for Q3FY25 were ₹10.20, marking a 20.0% increase from the previous year but a 7.3% decrease from the preceding quarter.
Operating Metrics
The total expenses for J B Chemicals & Pharmaceuticals Ltd in Q3FY25 were ₹753.50 crores. This represents a 12.8% increase from ₹667.91 crores in Q3FY24, indicating a growth in operational scale and associated costs. When compared to Q2FY25, total expenses decreased by 2.7% from ₹774.04 crores. This quarter-over-quarter decrease in expenses may reflect efficiency improvements or cost management efforts. The reduction in total expenses from the previous quarter alongside the increase in revenue from the same quarter last year highlights the company's operational adjustments within the fiscal year. These metrics are crucial for understanding the company's operational efficiency and cost management strategies.
